BioCentury | May 29, 2018
Company News

Management tracks: Axovant, Revance

...Clinical Advisory Board Chair Özlem Türeci as CMO, effective June 1. She was CEO at Ganymed Pharmaceuticals AG...
BioCentury | Nov 2, 2016
Company News

Ganymed, Astellas deal

...Astellas will acquire cancer company Ganymed for €422 million ($459.4 million) in cash. Ganymed shareholders are...
...for up to €860 million ($936.2 million) in undisclosed milestones tied to the development of Ganymed's...
...details. Ganymed Pharmaceuticals AG , Mainz, Germany Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Chris Lieu IMAB362 Astellas Pharma Inc. Ganymed Pharmaceuticals AG CLND18.2...
BioCentury | Oct 28, 2016
Company News

Astellas acquiring Ganymed

...is acquiring cancer company Ganymed Pharmaceuticals AG (Mainz, Germany) for EUR 422 million ($459.4 million) in cash. Ganymed...
...up to EUR 860 million ($936.2 million) in undisclosed milestones tied to the development of Ganymed's...
BioCentury | Jun 13, 2016
Clinical News

IMAB362: Phase II data

...adverse events. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Ganymed Pharmaceuticals AG...
BioCentury | Jun 7, 2016
Clinical News

Latest data show survival benefit for Ganymed's IMAB362

...Updated data presented at the American Society of Clinical Oncology (ASCO) meeting showed IMAB362 from Ganymed Pharmaceuticals AG...
...than for chemotherapy alone. An abstract released ahead of the conference had included interim data. Ganymed's...
...in the future from an exploratory 85-patient arm that received a higher dose of IMAB362. Ganymed...
BioCentury | Feb 5, 2015
Strategy

European mediation

...out a company while keeping the IP was partially based on the university's experiences with Ganymed Pharmaceuticals AG...
...Ganymed and transferred them to TRON after its foundation. "This was very important," Sahin said. "Ganymed's...
...Translational Molecule Medicine (CTMM), Eindhoven, the Netherlands Cluster for Individualized Immune Intervention (Ci3), Mainz, Germany Ganymed Pharmaceuticals AG...
BioCentury | Aug 18, 2014
Clinical News

IMAB362: Completed Phase II enrollment

...in the U.S. and EU for gastric cancer and in the EU for pancreatic cancer. Ganymed Pharmaceuticals AG...
BioCentury | Jun 2, 2014
Clinical News

IMAB362: Phase IIa data

...expressed in up to 80% of gastroesophageal adenocarcinomas and 60% of pancreatic tumors, according to Ganymed...
...in the U.S. and EU for gastric cancer and in the EU for pancreatic cancer. Ganymed Pharmaceuticals AG...
BioCentury | May 28, 2014
Clinical News

Ganymed reports IMAB362 data for gastroesophogeal cancer

...was 102 days. IMAB362 is a mAb targeting cell surface antigen targeting CLND18.2 , which Ganymed...
BioCentury | May 26, 2014
Finance

Europe's Iceberg 2014: Premier League teams

...Wellington Partners; Edmond de Rothschild Investment Partners; LSP-Life Sciences Partners; Wellcome Trust; Agentschap; INKEF Capital Ganymed Pharmaceuticals AG...
Items per page:
1 - 10 of 50
BioCentury | May 29, 2018
Company News

Management tracks: Axovant, Revance

...Clinical Advisory Board Chair Özlem Türeci as CMO, effective June 1. She was CEO at Ganymed Pharmaceuticals AG...
BioCentury | Nov 2, 2016
Company News

Ganymed, Astellas deal

...Astellas will acquire cancer company Ganymed for €422 million ($459.4 million) in cash. Ganymed shareholders are...
...for up to €860 million ($936.2 million) in undisclosed milestones tied to the development of Ganymed's...
...details. Ganymed Pharmaceuticals AG , Mainz, Germany Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Chris Lieu IMAB362 Astellas Pharma Inc. Ganymed Pharmaceuticals AG CLND18.2...
BioCentury | Oct 28, 2016
Company News

Astellas acquiring Ganymed

...is acquiring cancer company Ganymed Pharmaceuticals AG (Mainz, Germany) for EUR 422 million ($459.4 million) in cash. Ganymed...
...up to EUR 860 million ($936.2 million) in undisclosed milestones tied to the development of Ganymed's...
BioCentury | Jun 13, 2016
Clinical News

IMAB362: Phase II data

...adverse events. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Ganymed Pharmaceuticals AG...
BioCentury | Jun 7, 2016
Clinical News

Latest data show survival benefit for Ganymed's IMAB362

...Updated data presented at the American Society of Clinical Oncology (ASCO) meeting showed IMAB362 from Ganymed Pharmaceuticals AG...
...than for chemotherapy alone. An abstract released ahead of the conference had included interim data. Ganymed's...
...in the future from an exploratory 85-patient arm that received a higher dose of IMAB362. Ganymed...
BioCentury | Feb 5, 2015
Strategy

European mediation

...out a company while keeping the IP was partially based on the university's experiences with Ganymed Pharmaceuticals AG...
...Ganymed and transferred them to TRON after its foundation. "This was very important," Sahin said. "Ganymed's...
...Translational Molecule Medicine (CTMM), Eindhoven, the Netherlands Cluster for Individualized Immune Intervention (Ci3), Mainz, Germany Ganymed Pharmaceuticals AG...
BioCentury | Aug 18, 2014
Clinical News

IMAB362: Completed Phase II enrollment

...in the U.S. and EU for gastric cancer and in the EU for pancreatic cancer. Ganymed Pharmaceuticals AG...
BioCentury | Jun 2, 2014
Clinical News

IMAB362: Phase IIa data

...expressed in up to 80% of gastroesophageal adenocarcinomas and 60% of pancreatic tumors, according to Ganymed...
...in the U.S. and EU for gastric cancer and in the EU for pancreatic cancer. Ganymed Pharmaceuticals AG...
BioCentury | May 28, 2014
Clinical News

Ganymed reports IMAB362 data for gastroesophogeal cancer

...was 102 days. IMAB362 is a mAb targeting cell surface antigen targeting CLND18.2 , which Ganymed...
BioCentury | May 26, 2014
Finance

Europe's Iceberg 2014: Premier League teams

...Wellington Partners; Edmond de Rothschild Investment Partners; LSP-Life Sciences Partners; Wellcome Trust; Agentschap; INKEF Capital Ganymed Pharmaceuticals AG...
Items per page:
1 - 10 of 50